Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01419639 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2
A Phase 2 study of Neurofibromatosis Type II, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT01419639: Completed Phase 2 study of Neurofibromatosis Type II, sponsored by NYU Langone Health.
NCT01419639 is a Phase 2 study of Neurofibromatosis Type II that has completed, run by NYU Langone Health. The registered enrollment target is 10 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01419639, a Phase 2 study of Neurofibromatosis Type II, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial studies whether Everolimus is efficacious in treating neurofibromatosis 2.
Primary Outcome
To estimate the objective response rates to RAD001 in patients with NF2-related tumors including cranial nerve schwannomas, meningiomas and ependymomas. Radiographic response for study purposes = greater than or equal to 15% reduction in tumor volume in any of the target tumors (partial response). Complete disappearance of any of the target tumors = complete response. MRI of the brain and spine will be performed every 3 months. If an objective response (15% reduction in tumor volume compared to
Conditions Studied
Interventions
- DRUG Everolimus (RAD001) , Afinitor®
Study Locations (1)
New York
- New York University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2011-10 |
| Est. Completion | 2013-12 |
| Phase | Phase 2 |
What the finished NCT01419639 record still lists
NCT01419639 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Neurofibromatosis Type II appearing as the primary indexed condition, and to 1 intervention - of which Everolimus (RAD001) , Afinitor® is the first listed.
NCT01419639 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01419639 about?
NCT01419639 is a clinical study titled "Phase II Study of Everolimus (RAD001) in Children and Adults With Neurofibromatosis Type 2". This trial studies whether Everolimus is efficacious in treating neurofibromatosis 2.
What is the current status of trial NCT01419639?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2011-10. Estimated completion is 2013-12.
What conditions does trial NCT01419639 study?
This clinical trial studies the following conditions: Neurofibromatosis Type II.
What interventions are being tested in trial NCT01419639?
The interventions under investigation include: Everolimus (RAD001) , Afinitor® (DRUG).
Who is sponsoring clinical trial NCT01419639?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01419639 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01419639's enrollment target sits among peer trials
10 1968th of 2000 higher than 12 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia